Novel compounds as histone deacetylase inhibitors

a technology of histone deacetylase and compounds, which is applied in the field of new compounds as histone deacetylase inhibitors, can solve the problems of tumorigenic transformation, decrease of therapeutic doses, and destabilisation of the interaction of histones with dna, and achieve the effect of improving the condition of patients

Inactive Publication Date: 2005-08-11
4SC +1
View PDF2 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0058] They can also be used to support cell generation poiesis, including blood cell growth and generation (prohematopoietic effect) after depletion or destruction of cells, as caused by, for example, toxic agents, radiation, immunotherapy, growth defects, malnutrition, malabsorption, immune dysregulation, anemia and the like or to provide a therapeutic control of tissue generation and degradation, and therapeutic modification of cell and tissue maintenance and blood cell homeostasis.
[0059] The compounds according to the invention and medicaments prepared therewith are also useful for the treatment of a disease which is associated with gene-specific hypoacetylation of histones or other molecules, such as p53. Additionally, the compounds of the present invention may also be used in the treatment of conditions where the suppression of anti-apoptotic genes, such as BCL-XL and other BCL family members, or the induction of tumor suppressor activity of molecules such as p21 and/or p53, is required.
[0060] The compounds according to the invention and medicaments prepared therewith are also suitable for the treatment of diseases in which the induction of hyperacetylation of histones has a beneficial effect resulting in differentiation and/or apoptosis of a patient's tumor cells and thus causing a clinical improvement of the patient's condition. Examples of such diseases include but are not limited to, skin cancer, melanoma, estrogen receptor-dependent and independent breast cancer, ovarian cancer, testosteron receptor-dependent and independent prostate cancer, renal cancer, colon and colorectal cancer, pancreatic cancer, bladder cancer, esophageal cancer, stomach cancer, genitourinary cancer, gastrointestinal cancer, uterine cancer, astrocytomas, gliomas, basal cancer and squameous cell carcinoma, sarcomas as Kaposi's sarcoma and osteosarcoma, head and neck cancer, small cell and non-small cell lung carcinoma, leukemia, lymphomas and other blood cell cancers, Keratoakantoma, Bowen Disease, cutaneous T-Cell Lymphoma and also for the treatment of pre-malignant lesions (such as Actinic Keratose).
[0061] The combinatorial tr

Problems solved by technology

In the case of histone hyperacetylation, changes in electrostatic attraction for DNA and steric hindrance introduced by the hydrophobic acetyl group leads to destabilisation of the interaction of histones with DNA.
Disruption of these mechanisms gives rise to transcriptional misregu

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel compounds as histone deacetylase inhibitors
  • Novel compounds as histone deacetylase inhibitors
  • Novel compounds as histone deacetylase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Compound 1 (3-Cyclopentyl-N-hydroxy-propionamide)

[0085] To a solution of 3-Cyclopentyl-propionyl chloride (11.0 mL, 11.6 g, 72.0 mmol) in dichloromethane (50 mL) hydroxylamine hydrochloride (5.00 g, 72.0 mmol) and sodium bicarbonate (12.0 g, 144 mmol) were added. After stirring for 24 h at room temp. the reaction was quenched by addition of saturated ammonium chloride solution (50 mL). The layers were separated. The water layer was extracted with ethyl acetate (4×50 mL). The solvent of the combined organic layers was removed in vacuo. Precipitation of the crude product out of ethyl acetate by adding petroleum ether yielded the hydroxamate (5.25 g, 33.4 mmol, 46%) as a white solid. 1H NMR (300 MHz, [D6-DMSO]: δ=0.74-0.91 (m, 2H), 1.05-1.25 (m, 4H), 1.36 (q, J=7.4 Hz, 4H), 1.54-1.71 (m, 5H), 1.94 (t, J=7.6 Hz, 2H), 8.59 (s,1H) and 10.28 (s, 1H) (NH and OH). 13C NMR (75 MHz, [D6-DMSO]: δ=25.6, 26.0, 29.7, 32.4, 36.5, 169.2 (C(═O)NHOH). MS: m / z calcd for (C8H14NO2) [M+H]+...

example 2

Synthesis of Compound 2 (3-Cyclohexyl-N-hydroxy-propionamide):

[0086] To a solution of 3-Cyclohexyl-propionyl chloride (12.1 mL, 12.6 g, 72.0 mmol) in dichloromethane (50 mL) hydroxylamine hydrochloride (5.00 g, 72.0 mmol) and sodium bicarbonate (12.0 g, 144 mmol) were added. After stirring for 24 h at room temperature the reaction was quenched by addition of saturated ammonium chloride solution (50 mL). The layers were separated. The water layer was extracted with ethyl acetate (4×50 mL). The solvent of the combined organic layers was removed in vacuo. Precipitation of the crude product out of ethyl acetate by adding petroleum ether yielded the hydroxamate (7.21 g, 42 mmol, 58%) as a white solid. 1H-NMR (300 MHz, [D6-DMSO]: δ=0.95-1.12 (m, 2H), 1.38-1.69 (m, 6H), 1.62-1.77 (m, 3H), 1.94 (t, J=7.6 Hz, 2H), 8.58 (s, 1H) and 10.28 (s,1H) (NH and OH); 13C-NMR (75 MHz, [D6-DMSO]: δ=25.0, 31.8, 32.0, 32.3, 39.5, 169.5 (C(═)NHOH); MS: m / z calc. for (C9H17NO2) [M+H]+172; found 172.

example 3

Synthesis of Compound 3 (3-Cyclohexyl-N-hydroxy-acrylamide)

[0087] 3-Cyclohexyl-acrylic acid ethyl ester: to a cooled solution of oxalyl chloride (11.1 mL, 105 mmol) in dichloromethane (250 mL) was added at −78° C. a solution of dimethylsulfoxide (14.6 mL, 206 mmol) in dichloromethane (250 mL). After 5 min at the same temperature cyclohexylmethanol (10.8 mL, 87.5 mmol) and after additional 5 min triethylamine (60.7 mL, 438 mmol) were added. The reaction remained at −78° C. for two hours and then let warm to room temperature. The solvent was removed in vacuo. The resulting aldehyde was used for the next step without further purification. The crude cyclohexanecarbaldehyde was dissolved in toluene (200 mL) and ethanol (150 mL). After 15 min of stirring at 70° C. carbethoxy-methylene triphenylphosphorane (33.6 g, 96.5 mmol) was added in one portion. Stirring was continued for additional 24 hours. The solvent was removed in vacuo. The product was obtained by flash chromatography in 78% ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Electrical resistanceaaaaaaaaaa
Gene expression profileaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to compounds of the general formula (I)
or pharmaceutical acceptable salts or physiologically functional derivatives thereof wherein: n is a non-aromatic ring system containing two to seven carbon atoms, wherein the ring system can contain one ore two double bonds;
    • X is C, CH or CH2;
    • Y is selected from C, CH, CH2, S, NR, CH2-CH2,
    • H2C—CH, HC—CH2, C—CH2, H2C—C, or C—C; one or more of the hydrogen atoms can optionally be substituted by one or more substituents R′; each of the dotted lines means a single, a double or triple bond with the exclusion of a combination of a triple with triple bond and a double with a triple bond; R′ is independently H, —CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogene, haloalkyl, haloalkyloxy; R is H, an alkyl or cycloalkyl group; Z is CH, C, or P; p is 0 or 1.

Description

[0001] The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and / or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and / or induction of differentiation and / or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression. BACKGROUND OF THE INVENTION [0002] Local remodeling of chromatin is a key step in the transcriptional activation of genes. Dynamic changes in the nucleosomal packaging of DNA must occur to allow transcriptional proteins to contact with the DNA template. One of the most important mechanisms influencing chromatin remod...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/19A61K31/66C07C259/04
CPCC07C259/04C07C2101/14C07C2101/08C07C2601/08C07C2601/14A61P35/00
Inventor MAURER, ALEXANDER B.HOEVELMANN, SASCHAMARTIN, ELKEHENTSCH, BERNDGASSEN, MICHAELKRAUS, JUERGENKRAUSS, ROLFVINCEK, ADAM-SPENCER
Owner 4SC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap